| Dr. Jason E. Frankel Musculoskeletal Therapy & Rehabilitation, Inc. | |
|
30 W Avon Rd, Suite B, Avon, CT 06001-3678 | |
| (860) 675-9500 | |
| (860) 675-9600 |
| Full Name | Dr. Jason E. Frankel Musculoskeletal Therapy & Rehabilitation, Inc. |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 30 W Avon Rd, Avon, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457378291 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 001633 (Connecticut) | Primary |
| Provider Name | Jason Edward Frankel |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1396792792 PECOS PAC ID: 6507874633 Enrollment ID: I20060330000637 |
News Archive
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.
A tremendous amount of Amyloid-β peptide (Aβ) (a peptide of ～40 amino acids) accumulates in the brain of Alzheimer's disease patients. γ-Secretase inhibitors were designed to inhibit the enzymatic activity that produces Aβ. By reducing Aβ production, γ-secretase inhibitors were considered able to treat Alzheimer's disease (Aβ hypothesis).
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
A fascinating new study, released as a preprint on the medRxiv* server, adds a highly appealing tool to the armory of detection techniques for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its validation could allow the early and accurate detection of recent or active infection, which is valuable in tracing contacts and preventing forward transmission of the virus.
Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr. Jason E. Frankel Musculoskeletal Therapy & Rehabilitation, Inc. 30 W Avon Rd, Suite B, Avon, CT 06001-3678 Ph: (860) 675-9500 | Dr. Jason E. Frankel Musculoskeletal Therapy & Rehabilitation, Inc. 30 W Avon Rd, Suite B, Avon, CT 06001-3678 Ph: (860) 675-9500 |
News Archive
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.
A tremendous amount of Amyloid-β peptide (Aβ) (a peptide of ～40 amino acids) accumulates in the brain of Alzheimer's disease patients. γ-Secretase inhibitors were designed to inhibit the enzymatic activity that produces Aβ. By reducing Aβ production, γ-secretase inhibitors were considered able to treat Alzheimer's disease (Aβ hypothesis).
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
A fascinating new study, released as a preprint on the medRxiv* server, adds a highly appealing tool to the armory of detection techniques for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its validation could allow the early and accurate detection of recent or active infection, which is valuable in tracing contacts and preventing forward transmission of the virus.
Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.
› Verified 4 days ago
Dr. Timothy Stone Owens, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 12 W Avon Rd, Avon, CT 06001 Phone: 860-673-5665 Fax: 860-673-2084 | |
Siegel Chiropractic, Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 28 E Main St, Avon, CT 06001 Phone: 860-674-1992 Fax: 860-674-9664 | |
Koster Family Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 152 Simsbury Rd # 12e, Building 19, Avon, CT 06001 Phone: 860-677-1100 Fax: 860-677-1139 | |
Dr. Patricia Brady-lux, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 12 W Avon Rd, Avon, CT 06001 Phone: 860-673-5665 | |
Nardi Family Chiropractic, Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 195 W Main St, Avon, CT 06001 Phone: 860-677-6401 Fax: 860-677-6873 | |
Dr. David S Schiller, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 25 Bailey Rd, Avon, CT 06001 Phone: 860-676-9660 Fax: 860-676-9159 | |
Jason E Frankel, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 30 W Avon Rd, Avon, CT 06001 Phone: 860-675-9500 Fax: 860-675-9600 |